SOUTH SAN FRANCISCO, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that company research will be presented at the upcoming American Heart Association (AHA) Scientific Sessions 2017 taking place November 11-15, 2017 in Anaheim, California.
Among the science being featured at this year’s AHA will be an oral presentation during the Late-Breaking Basic Science session of results from MyoKardia’s substudy to assess the ability of a wrist-worn, biosensor to potentially serve as a non-invasive means for obstructive hypertrophic cardiomyopathy (oHCM) patient identification. The substudy was conducted as part of MyoKardia’s PIONEER-HCM trial of its investigational drug, mavacamten (formerly MYK-461).
A complete list of planned MyoKardia research presentations is detailed below:
Machine Learning Detection of Obstructive Hypertrophic Cardiomyopathy Using a Wearable Biosensor (#807)
Date & time: Monday, November 13, 2017 at 4:15 pm PT
Session: Late-Breaking Basic Science Oral Abstract
A Novel Mini-Pig Genetic Model of Hypertrophic Cardiomyopathy: Altered Myofilament Dynamics, Hyper-Contractility and Impaired Systolic/Diastolic Function Reserve In Vivo (#5059)
Date & time: Sunday, November 12, 2017 at 3:15 pm PT
Session: Heart Failure and Cardiomyopathies: General Topics IV
In Vivo Cardiac Effects of Mavacamten (MYK-461): Evidence for Negative Inotropy and Improved Compliance (#405)
Date & time: Tuesday, November 14, 2017 at 6:00 pm PT
Session: Drug Discovery for Heart Failure
About Mavacamten (MYK-461)
Mavacamten is a novel, oral, allosteric modulator of cardiac myosin that reduced hypercontractility in a Phase 1 clinical study of hypertrophic cardiomyopathy (HCM) patients. MyoKardia has evaluated mavacamten in multiple Phase 1 clinical studies, primarily designed to evaluate safety and tolerability of oral doses of mavacamten, and provide pharmacokinetic and pharmacodynamic data. In April 2016, the U.S. FDA granted Orphan Drug Designation for mavacamten for the treatment of symptomatic oHCM, a subset of HCM. MyoKardia is currently studying mavacamten in the Phase 2 PIONEER-HCM study.
MyoKardia is a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases. MyoKardia’s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy—hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). MyoKardia’s most advanced product candidate is mavacamten (formerly MYK-461), a novel, oral, allosteric modulator of cardiac myosin that has been shown to reduce hypercontractility in early clinical studies and is currently being studied in the Phase 2 PIONEER-HCM clinical trial. MYK-491, MyoKardia’s second product candidate, is designed to increase the overall extent of the heart’s contraction in DCM patients by increasing cardiac contractility. MyoKardia is currently evaluating MYK-491 in a Phase 1 study in healthy volunteers. A cornerstone of the MyoKardia platform is the Sarcomeric Human Cardiomyopathy Registry (SHaRe), a multi-center, international repository of clinical and laboratory data on individuals and families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia’s mission is to change the world for patients with serious cardiovascular disease through bold and innovative science.